One of the few late-stage ALS contenders hits a critical juncture

The early-stage pipeline for amyotrophic lateral sclerosis drugs exploded last year. After ALS R&D notched 28 new trial starts in 2023, the rate more than doubled to 60 in 2024, Citeline recently reported.

Late-stage contenders are harder to come by, though, with just a handful of treatments in phase 3, according to ClinicalTrials.gov.

But for an illness beset by high-profile setbacks in recent years and a lack of disease-modifying options, the opportunity for each remaining candidate to deliver a breakthrough looms large.